Albert C M Ong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5847025/publications.pdf

Version: 2024-02-01

167 papers	6,824 citations	57631 44 h-index	69108 77 g-index

260 all docs	260 docs citations	260 times ranked	6229 citing authors

#	Article	IF	Citations
1	An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrology Dialysis Transplantation, 2022, 37, 825-839.	0.4	44
2	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	2.6	62
3	Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response. CKJ: Clinical Kidney Journal, 2022, 15, 1160-1168.	1.4	2
4	Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. Human Molecular Genetics, 2022, 31, 1560-1573.	1.4	11
5	Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't. CKJ: Clinical Kidney Journal, 2022, 15, 1034-1036.	1.4	6
6	FC029: A Multivariate Model Identifies Genotype, Hypertension and Kidney Length as Independent Baseline Predictors of Disease Progression in a Longitudinal Autosomal Dominant Polycystic Kidney Disease Patient Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
7	MO030: Familial clustering of a rare UMOD variant in undiagnosed hereditary nephropathy suggests the presence of a common ancestral founder mutation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
8	MO015: The Interaction of Gender and Genotype in the Development of Polycystic Liver Disease in ADPKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
9	Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership. BMJ Open, 2022, 12, e055780.	0.8	3
10	Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. CKJ: Clinical Kidney Journal, 2022, 15, 2063-2071.	1.4	3
11	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
12	Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. Genetics in Medicine, 2021, 23, 689-697.	1.1	31
13	Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. Renal Failure, 2021, 43, 1-15.	0.8	25
14	Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone. CKJ: Clinical Kidney Journal, 2021, 14, 1715-1718.	1.4	2
15	MO023FLANK PAIN HAS A MAJOR NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE IN ADPKD: THE CYSTIC I STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
16	An Nphp1 knockout mouse model targeting exon 2â€“20 demonstrates characteristic phenotypes of human nephronophthisis. Human Molecular Genetics, 2021, 31, 232-243.	1.4	9
17	TAMEing ADPKD with metformin: safe and effective?. Kidney International, 2021, 100, 513-515.	2.6	6
18	Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?. Nephrology Dialysis Transplantation, 2020, 35, 198-203.	0.4	12

#	Article	IF	Citations
19	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	2.6	44
20	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	0.8	5
21	SAT-442 Identification of Exosome MicroRNAs as Novel Biomarkers for Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2020, 5, S185.	0.4	0
22	The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 8936.	1.8	13
23	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	2.6	27
24	SO092REDUCED QUALITY OF LIFE IN ADPKD PATIENTS WITH CKD STAGE 1-3: THE CYSTIC I QUALITY OF LIFE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
25	Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open, 2020, 10, e032620.	0.8	27
26	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	2.1	23
27	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	2.1	16
28	The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis inÂvitro is counteracted by increased kidney inflammation inÂvivo. Kidney International, 2020, 98, 404-419.	2.6	25
29	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	2.6	40
30	A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2â^'/â^' phenotype. Scientific Reports, 2020, 10, 72.	1.6	18
31	Post-translational modifications of the polycystin proteins. Cellular Signalling, 2020, 72, 109644.	1.7	7
32	Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling. JCI Insight, 2020, 5, .	2.3	25
33	SAT-100 â€œA SWORD OF DAMOCLESâ€• PATIENT AND CAREGIVER BELIEFS, ATTITUDES AND PERSPECTIVES ON GENETIC SCREENING AND TESTING FOR AUTOSOMAL POLYCYSTIC KIDNEY DISEASE - FOCUS GROUP STUDY. Kidney International Reports, 2019, 4, S48.	0.4	0
34	FO026GLOBAL MICRORNA PROFILING IN HUMAN URINARY EXOSOMES REVEALS NEW DISEASE BIOMARKERS AND CELLULAR PATHWAYS FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
35	SAT-334 GENETIC TESTING OF FAMILIES WITH VERY EARLY ONSET POLYCYSTIC KIDNEY DISEASE REVEALS THE FUNCTIONAL SIGNIFICANCE OF HYPOMORPHIC VARIANTS. Kidney International Reports, 2019, 4, S148.	0.4	0
36	Identifying patientâ€•important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20

#	Article	IF	Citations
37	A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. European Radiology, 2019, 29, 4188-4197.	2.3	16
38	Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13320-13329.	3.3	54
39	SaO005CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
40	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. Frontiers in Neurology, 2019, 10, 1116.	1.1	11
41	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. Radiology, 2019, 290, 769-782.	3.6	69
42	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation, 2018, 33, 563-573.	0.4	28
43	Tolvaptan slows disease progression in late-stage ADPKD. Nature Reviews Nephrology, 2018, 14, 146-148.	4.1	12
44	A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrology, 2018, 19, 37.	0.8	34
45	Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD. American Journal of Kidney Diseases, 2018, 71, 912-913.	2.1	4
46	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 1310-1316.	0.4	27
47	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.4	91
48	Imaging of kidney cysts and cystic kidney diseases in children. Consensus paper by an ad hoc committee. Ultraschall in Der Medizin, 2018, 39, .	0.8	0
49	STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney International, 2017, 91, 575-586.	2.6	41
50	Making sense of polycystic kidney disease. Lancet, The, 2017, 389, 1780-1782.	6.3	9
51	The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex. Journal of the American Society of Nephrology: JASN, 2017, 28, 2973-2984.	3.0	20
52	Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. American Journal of Physiology - Renal Physiology, 2017, 312, F577-F588.	1.3	26
53	Development of a rapid semi-automated tool to measure total kidney volume in autosomal dominant polycystic kidney disease. Lancet, The, 2017, 389, S90.	6.3	0
54	TO033VERY EARLY-ONSET AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE DUE TO BI-ALLELIC MUTATIONS IN PKD1 AND PKD2. Nephrology Dialysis Transplantation, 2017, 32, iii94-iii94.	0.4	0

#	Article	IF	Citations
55	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 2144-2144.	0.4	11
56	Standardised Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	0.7	20
57	SO052DEVELOPMENT OF A RAPID SEMI-AUTOMATED TOOL TO MEASURE TOTAL KIDNEY VOLUME IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i22.	0.4	0
58	SO053SELECTIVE PROSTAGLANDIN E2 RECEPTOR BLOCKADE FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i23.	0.4	0
59	The Cyclic AMP Signaling Pathway and Direct PKA Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. Biophysical Journal, 2016, 110, 611a-612a.	0.2	0
60	The Polycystin-1, Lipoxygenase, and Î±-Toxin Domain Regulates Polycystin-1 Trafficking. Journal of the American Society of Nephrology: JASN, 2016, 27, 1159-1173.	3.0	29
61	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.4	206
62	Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1130-1140.	0.4	38
63	Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Research, 2016, 5, 2029.	0.8	17
64	New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol: FigureÂ1. BMJ Open, 2015, 5, e008440.	0.8	3
65	Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease. Transplantation, 2015, 99, 1023-1029.	0.5	18
66	FP064ASSESSING THE LONG TERM OUTCOMES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) USING THE ADPKD OUTCOMES MODEL: A UK CASE STUDY. Nephrology Dialysis Transplantation, 2015, 30, iii85-iii86.	0.4	1
67	SuO042POLYCYSTIN-1 TRAFFICKING IS REGULATED BY CAMP DEPENDENT PHOSPHORYLATION OF THE PLAT DOMAIN. Nephrology Dialysis Transplantation, 2015, 30, iii63-iii63.	0.4	0
68	FP364INCREASED PSYCHOSOCIAL BURDEN AND ADVERSE QUALITY OF LIFE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii190-iii190.	0.4	0
69	Backbone assignment and secondary structure of the PLAT domain of human polycystin-1. Biomolecular NMR Assignments, 2015, 9, 369-373.	0.4	1
70	Endothelin and Tubulointerstitial Renal Disease. Seminars in Nephrology, 2015, 35, 197-207.	0.6	16
71	A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney International, 2015, 88, 699-710.	2.6	140
72	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	6.3	227

#	Article	IF	Citations
73	The cAMP Signaling Pathway and Direct Protein Kinase A Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. Journal of Biological Chemistry, 2015, 290, 23888-23896.	1.6	21
74	Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 197-203.	0.4	38
75	Autosomal dominant polycystic kidney disease. , 2015, , 2625-2626.		0
76	Autosomal dominant polycystic kidney disease. , 2015, , 2627-2633.		1
77	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.4	11
78	How simple are 'simple renal cysts'?. Nephrology Dialysis Transplantation, 2014, 29, iv106-iv112.	0.4	44
79	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	2.6	91
80	RENAL DEVELOPMENT AND CYSTIC DISEASES. Nephrology Dialysis Transplantation, 2014, 29, iii73-iii78.	0.4	0
81	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.4	180
82	Fabrication and Luminescence of Monolayered Boron Nitride Quantum Dots. Small, 2014, 10, 60-65.	5.2	196
83	Development Of A Model To Predict Disease Progression In Autosomal Dominant Polycystic Kidney Disease (ADPKD). Value in Health, 2014, 17, A564.	0.1	0
84	Sudden death due to subarachnoid haemorrhage in an infant with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, iv121-iv123.	0.4	10
85	Angiopoietin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: Role of eNOS and VE-cadherin. Pharmacological Research, 2014, 80, 43-51.	3.1	31
86	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	6.3	194
87	TRPP2 in Polycystic Kidney Disease. , 2014, , 491-522.		0
88	Genetics and Genomics of Chronic Kidney Disease. , 2014, , 369-392.		0
89	Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Archiv European Journal of Physiology, 2013, 466, 1591-604.	1.3	20
90	Fabrication of Luminescent Monolayered Tungsten Dichalcogenides Quantum Dots with Giant Spin-Valley Coupling. ACS Nano, 2013, 7, 8214-8223.	7.3	181

#	Article	IF	Citations
91	Cystic kidney diseases: many ways to form a cyst. Pediatric Nephrology, 2013, 28, 33-49.	0.9	28
92	The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 639-646.	0.2	34
93	Primary cilia and renal cysts: does length matter?. Nephrology Dialysis Transplantation, 2013, 28, 2661-2663.	0.4	12
94	Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H33-H41.	1.5	25
95	Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in <i>LMNA</i>. Nephron Clinical Practice, 2013, 124, 31-37.	2.3	29
96	Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Human Molecular Genetics, 2013, 22, 1924-1939.	1.4	47
97	New treatments for autosomal dominant polycystic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, n/a-n/a.	1.1	37
98	The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease. PLoS ONE, 2013, 8, e73173.	1.1	25
99	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.4	10
100	Spurious hypophosphatemia associated with monoclonal paraproteinemia. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 693-696.	0.2	9
101	Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects. Nephron Clinical Practice, 2012, 120, c25-c35.	2.3	61
102	Whatâ€™s new inâ€¦ Ciliopathies. Medicine, 2011, 39, 119-125.	0.2	0
103	32 PKD2 mutant zebrafish display excessive developmental angiogenesis. Heart, 2011, 97, e7-e7.	1.2	0
104	Endothelin in Polycystic Kidney Disease. Contributions To Nephrology, 2011, 172, 200-209.	1.1	12
105	Towards the Integration of Genetic Knowledge into Clinical Practice. Nephron Clinical Practice, 2011, 118, c3-c8.	2.3	4
106	A Single Amino Acid Residue Constitutes the Third Dimerization Domain Essential for the Assembly and Function of the Tetrameric Polycystin-2 (TRPP2) Channel. Journal of Biological Chemistry, 2011, 286, 18994-19000.	1.6	22
107	Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity. American Journal of Physiology - Renal Physiology, 2011, 300, F1375-F1384.	1.3	6
108	A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO Journal, 2010, 29, 1176-1191.	3.5	70

#	Article	IF	Citations
109	Protein Kinase Dâ€“mediated Phosphorylation of Polycystin-2 (TRPP2) Is Essential for Its Effects on Cell Growth and Calcium Channel Activity. Molecular Biology of the Cell, 2010, 21, 3853-3865.	0.9	36
110	Structural and Molecular Basis of the Assembly of the TRPP2/PKD1 Complex. Biophysical Journal, 2010, 98, 344a.	0.2	0
111	Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11558-11563.	3.3	163
112	Autosomal dominant polycystic kidney disease. Clinical Medicine, 2009, 9, 278-283.	0.8	13
113	Screening for intracranial aneurysms in ADPKD. BMJ: British Medical Journal, 2009, 339, b3763-b3763.	2.4	21
114	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. Journal of Cell Science, 2009, 122, 1410-1417.	1.2	48
115	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. Journal of Cell Science, 2009, 122, 1702-1702.	1.2	0
116	A novel dephosphorylationâ€activated conductance in a mouse renal collecting duct cell line. Experimental Physiology, 2009, 94, 914-927.	0.9	2
117	Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease â€“ Future Promise, Present Fears. Nephron Clinical Practice, 2009, 112, c230-c241.	2.3	21
118	Activation of TRPP2 through mDia1-dependent voltage gating. EMBO Journal, 2008, 27, 1345-1356.	3.5	37
119	Identification and Functional Characterization of an N-terminal Oligomerization Domain for Polycystin-2. Journal of Biological Chemistry, 2008, 283, 28471-28479.	1.6	50
120	Autosomal Dominant Polycystic Kidney Disease: Recent Advances in Pathogenesis and Treatment. Nephron Physiology, 2008, 108, p1-p7.	1.5	63
121	Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney International, 2007, 72, 157-165.	2.6	74
122	Endothelin B Receptor Blockade Accelerates Disease Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 560-569.	3.0	40
123	Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation. Transplantation, 2007, 83, 36-40.	0.5	90
124	Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease. American Journal of Pathology, 2007, 170, 830-842.	1.9	118
125	Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrology Dialysis Transplantation, 2006, 21, 2078-2084.	0.4	78
126	Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Human Molecular Genetics, 2006, 16, 265-275.	1.4	129

#	Article	IF	Citations
127	Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. Human Molecular Genetics, 2006, 15, 1465-1473.	1.4	83
128	Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney International, 2005, 67, 1234-1247.	2.6	202
129	Detection of Proximal Tubular Motile Cilia in a Patient With Renal Sarcoidosis Associated With Hypercalcemia. American Journal of Kidney Diseases, 2005, 45, 1096-1099.	2.1	26
130	Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected. Journal of Biological Chemistry, 2004, 279, 27472-27481.	1.6	40
131	Genetic Renal Abnormalities. Medicine, 2003, 31, 32-35.	0.2	0
132	Polycystic kidney diseaseâ€"the ciliary connection. Lancet, The, 2003, 361, 774-776.	6.3	130
133	Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet, The, 2003, 361, 2196-2201.	6.3	198
134	Expression and Cellular Localisation of Renal Endothelin-1 and Endothelin Receptor Subtypes in Autosomal-Dominant Polycystic Kidney Disease. Nephron Experimental Nephrology, 2003, 93, e80-e86.	2.4	27
135	Functional Analysis of PKD1 Transgenic Lines Reveals a Direct Role for Polycystin-1 in Mediating Cell-Cell Adhesion. Journal of the American Society of Nephrology: JASN, 2003, 14, 1804-1815.	3.0	77
136	Identification, Characterization, and Localization of a Novel Kidney Polycystin-1-Polycystin-2 Complex. Journal of Biological Chemistry, 2002, 277, 20763-20773.	1.6	178
137	Polycystin-2 expression is increased following experimental ischaemic renal injury. Nephrology Dialysis Transplantation, 2002, 17, 2138-2144.	0.4	18
138	Polycystin Expression in the Kidney and Other Tissues: Complexity, Consensus and Controversy. Nephron Experimental Nephrology, 2000, 8, 208-214.	2.4	30
139	Cyst formation in ADPKD: new insights from natural and targeted mutants. Nephrology Dialysis Transplantation, 1999, 14, 544-546.	0.4	1
140	Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney International, 1999, 56, 1324-1333.	2.6	87
141	Coordinate Expression of the Autosomal Dominant Polycystic Kidney Disease Proteins, Polycystin-2 And Polycystin-1, in Normal and Cystic Tissue. American Journal of Pathology, 1999, 154, 1721-1729.	1.9	174
142	An unusual complication of pregnancy. Nephrology Dialysis Transplantation, 1999, 14, 1324-1326.	0.4	0
143	Regional Variations in Endothelin-1 and its Receptor Subtypes in Human Coronary Vasculature: Pathophysiological Implications in Coronary Disease. Endothelium: Journal of Endothelial Cell Research, 1998, 6, 61-70.	1.7	32
144	Molecular basis of renal cyst formationâ€"one hit or two?. Lancet, The, 1997, 349, 1039-1040.	6.3	47

#	Article	IF	Citations
145	Identification of Mutations in the Duplicated Region of the Polycystic Kidney Disease 1 Gene (PKD1) by a Novel Approach. American Journal of Human Genetics, 1997, 60, 1399-1410.	2.6	100
146	Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. Bone, 1996, 18, 159-169.	1.4	72
147	Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1524-1528.	3.3	239
148	A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). Human Molecular Genetics, 1996, 5, 539-542.	1.4	94
149	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrology Dialysis Transplantation, 1996, 11, 251-257.	0.4	14
150	Surprising new roles for endothelins. BMJ: British Medical Journal, 1996, 312, 195-196.	2.4	6
151	An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney International, 1995, 48, 390-401.	2.6	99
152	Oncogenous hypophosphataemic osteomalacia: effects on phosphate transport and vitamin D metabolism in cultured human kidney cells. Bone, 1995, 16, 679.	1.4	0
153	Tubular-derived cytokines and human renal disease progression. Nephrology Dialysis Transplantation, 1994, 9, 471-472.	0.4	8
154	Tubular lipidosis: Epiphenomenon or pathogenetic lesion in human renal disease?. Kidney International, 1994, 45, 753-762.	2.6	34
155	Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. Kidney International, 1994, 46, 1315-1321.	2.6	49
156	Loss of glomerular function and tubulointerstitial fibrosis:Cause or effect?. Kidney International, 1994, 45, 345-351.	2.6	111
157	Tubular-Derived Growth Factors and Cytokines in the Pathogenesis of Tubulointerstitial Fibrosis: Implications for Human Renal Disease Progression. American Journal of Kidney Diseases, 1994, 23, 205-209.	2.1	81
158	Mechanisms of tubulo-interstitial injury in progressive renal diseases. European Journal of Clinical Investigation, 1993, 23, 259-265.	1.7	94
159	Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrology Dialysis Transplantation, 1993, 8, 748-753.	0.4	40
160	Sinus arrest and asystole due to severe lithium intoxication. International Journal of Cardiology, 1991, 30, 364-366.	0.8	16
161	The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clinical Endocrinology, 1991, 34, 43-49.	1.2	101
162	The Use of Lithium Clearance in Bartter's Syndrome. Nephrology Dialysis Transplantation, 1990, 5, 904-905.	0.4	1

#	Article	IF	Citations
163	Atrial natriuretic peptide release responds to atrial stretch and not to atrial pressure: observations during pericardiocentesis in a young woman. European Heart Journal, 1990, 11, 368-371.	1.0	23
164	Intermittent absorption of warfarin caused by an unrecognized pharyngeal pouch.. Postgraduate Medical Journal, 1989, 65, 660-661.	0.9	2
165	Effects of noradrenaline infusion on platelet catecholamine levels and platelet aggregation. Journal of Hypertension, 1989, 7, S166-167.	0.3	4
166	Hypersensitivity vasculitis complicating intravenous streptokinase therapy in acute myocardial infarction. International Journal of Cardiology, 1988, 21, 71-73.	0.8	22
167	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrology Dialysis Transplantation, 0, , .	0.4	4